Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 7, 2011, Pages 1502-1515

  Crooke, Philip S ^a   Justenhoven, Christina ^b,c   Brauch, Hiltrud ^b,c   Dawling, Sheila ^a   Roodi, Nady ^a   Higginbotham, Kathryn S P ^a   Plummer, W Dale ^a   Schuyler, Peggy A ^a   Sanders, Melinda E ^a   Page, David L ^a   Smith, Jeffrey R ^a   Dupont, William D ^a   Parl, Fritz F ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYESTRADIOL; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BODY MASS; BREAST CANCER; CANCER MODEL; CANCER RISK; CONTROLLED STUDY; ESTROGEN METABOLISM; FAMILY HISTORY; FEMALE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; ALGORITHMS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A1; ESTRADIOL; ESTROGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; PHENOTYPE; RISK FACTORS;

EID: 79960093250     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0060     Document Type: Article

References (86)

1. MacMahon B, Feinleib M. Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst 1960;24:733-53.
2. Parl FF. Estrogens, estrogen receptor and breast cancer. Amsterdam, the Netherlands: IOS Press; 2000.
3. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983;303:767-70.
4. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
5. Devanesan P, Santen RJ, Bocchinfuso WP, Korach KS, Rogan EG, Cavalieri E. Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-a knockout (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors. Carcinogenesis 2001;22:1573-6. (Pubitemid 32898717)
6. Rogan EG, Badawi AF, Devanesan PD, Meza J, Edney JA, West WW, et al. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003;24:697-702. (Pubitemid 36592404)
7. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27. (Pubitemid 28376821)
8. Cavalieri EL, Stack DE, Devanesan PD, Todorvic R, Dwivedy I, Higginbotham S, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997;94:10937-42. (Pubitemid 27430839)
9. Li KM, Todorovic R, Devanesan P, Higginbotham S, Kofeler H, Ramanathan R, et al. Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 2004;25:289-97. (Pubitemid 38239812)
10. Fernandez SV, Russo IH, Russo J. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer 2006;118:1862-8.
11. Zhao Z, Kosinska W, Khmelnitsky M, Cavalieri EL, Rogan EG, Chakravarti D, et al. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB Rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem Res Toxicol 2006;19:475-9.
12. Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM, et al. 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 2006;20:1622-34. (Pubitemid 44943799)
13. Shekhar MP, Nangia-Makker P, Wolman SR, Tait L, Heppner GH, Visscher DW. Direct action of estrogen on sequence of progression of human preneoplastic breast disease. Am J Pathol 1998;152:1129-32. (Pubitemid 28221863)
14. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-7. (Pubitemid 30070740)
15. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86. (Pubitemid 37412587)
16. Embrechts J, Lemiere F, Van Dongen W, Esmans EL, Buytaert P, Van Marck E, et al. Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry. J Am Soc Mass Spectrom 2003;14:482-91. (Pubitemid 36871629)
17. Markushin Y, Zhong W, Cavalieri EL, Rogan EG, Small GJ, Yeung ES, et al. Spectral characterization of catechol estrogen quinone (CEQ)-derived DNA adducts and their identification in human breast tissue extract. Chem Res Toxicol 2003;16:1107-17. (Pubitemid 37163216)
18. Zhang Q, Aft RL, Gross ML. Estrogen carcinogenesis: specific identification of estrorgen-modified nucleobase in breast tissue from women. Chem Res Toxicol 2008;21:1509-13.
19. Belous AR, Hachey DL, Dawling S, Roodi N, Parl FF. Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Res 2007;67:812-7. (Pubitemid 46192222)
20. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33. (Pubitemid 30137927)
21. www.cancer.gov/bcrisktool.
22. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. New Engl J Med 2000;342:564-71. (Pubitemid 30117898)
23. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
24. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86. (Pubitemid 20026073)
25. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-66. (Pubitemid 32229380)
26. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Statist Med 2004;23:1111-30. (Pubitemid 38477070)
27. Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF. Estrogens, enzyme variants, and breast cancer: a risk model. Cancer Epidemiol Biomarkers Prev 2006;15:1620-9. (Pubitemid 44497096)
28. Cavalieri EL, Li KM, Balu N, Saeed M, Devanesan P, Higginbotham S, et al. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 2002;23:1071-7. (Pubitemid 34752965)
29. Dawling S, Hachey DL, Roodi N, Parl FF. In vitro model of mammary estrogen metabolism: structural and kinetic differences in mammary metabolism of catechol estrogens 2- and 4-hydroxyestradiol. Chem Res Toxicol 2004;17:1258-64.
30. Dawling S, Roodi N, Mernaugh RL, Wang XY, Parl FF. Catechol- Omethyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001;61:6716-22. (Pubitemid 32896493)
31. Hachey DL, Dawling S, Roodi N, Parl FF. Sequential action of phase I and II enzymes cytochrome P450 1B1 and glutathione S-transferase P1 in mammary estrogen metabolism. Cancer Res 2003;63:8492-9. (Pubitemid 37549506)
32. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-4. (Pubitemid 30482162)
33. Parl FF, Egan KM, Li C, Crooke PS. Estrogen exposure, metabolism, and enzyme variants in a model for breast cancer risk prediction. Cancer Informatics 2009;7:109-21.
34. Castagnetta LAM, Granata OM, Traina A, Ravazzolo B, Amoroso M, Miele M, et al. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 2002;8:3146-55. (Pubitemid 35155024)
35. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 1986;24:353-6.
36. Han X, Liehr JG. 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. Cancer Res 1994;54:5515-7. (Pubitemid 24346236)
37. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996;93:3294-6. (Pubitemid 26125612)
38. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 2008;108:137-49. (Pubitemid 351623246)
39. Pesch B, Ko YD, Brauch H, Hamann U, Harth V, Rabstein S, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 2005;20:699-711. (Pubitemid 41266867)
40. Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, et al. The CYP1B1-1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 2008;111:171-7. (Pubitemid 352009231)
41. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51. (Pubitemid 15192861)
42. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-708.
43. Dupont WD, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, Sanders ME, et al. Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk. Cancer 2010;116:8-19.
44. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998;122:1053-5.
45. Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh, Scotland: Churchill Livingstone; 1987.
46. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat 1998;51:195-208. (Pubitemid 29054554)
47. Page DL, Jensen RA, Simpson JF. Premalignant and malignant disease of the breast: the roles of the pathologist. Mod Pathol 1998;11:120-8. (Pubitemid 28144147)
48. Kirkpatrick S, Gelatt CD, Vecchi MP. Optimization by simulated annealing. Science 1983;220:671-80.
49. Nelder JA, Mead R. A simplex method for function minimization. Comput J 1965;7:308-13.
50. Storn R, Price K. Differential evolution-a simple and efficient heuristic for global optimization over continuous spaces. J Global Optimization 1997;11:341-59. (Pubitemid 127502202)
51. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
52. Schafer JL. Analysis of incomplete multivariate data. Boca Raton, FL: Chapman & Hall/CRC; 1997.
53. StataCorp. Stata statistical software: Release 11. Multiple imputation. College Station, TX: Stata Corporation; 2009.
54. Delong ER, Delong DM, Clarkepearson DI. Comparing the areas under 2 or more correlated receiver operating characteristic curves-a nonparametric approach. Biometrics 1988;44:837-45.
55. StataCorp. Stata statistical software: Release 11. College Station, TX: Stata Corporation; 2009.
56. Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54. (Pubitemid 29508718)
57. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutation Res 2003;544:9-41.
58. Low YL, Li Y, Humphreys K, Thalamuthu A, Li Y, Darabi H, et al. Multivariant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLos Genet 2010.p. e1001012.
59. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138-47. (Pubitemid 32614026)
60. Thomas DC. The need for a systematic approach to complex pathways in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:557-9. (Pubitemid 40489193)
61. Parl FF, Crooke PS, Conti DV, Thomas DC. Pathway-based methods in molecular cancer epidemiology. In:Rebbeck TR, Ambrosone CB, Shields PG, editors. Molecular epidemiology applications in cancer and other human diseases. New York: Informa Healthcare; 2008. p. 189-204.
62. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59.
63. Shen L, Pisha E, Huang Z, Pezzuto JM, Krol E, Alam Z, et al. Bioreductive activation of catechol estrogen-ortho-quinones: aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity. Carcinogenesis 1997;18:1096-101.
64. Pisha E, Lui X, Constantinou AI, Bolton JL. Evidence that a metabolite of equine estrogens, 4-hydroxyequilenin, induces cellular transformation in vitro. Chem Res Toxicol 2001;14:82-90. (Pubitemid 32064378)
65. Zhang F, Swanson SM, Van Breemen RB, Liu X, Yang Y, Gu C, et al. Equine estrogen metabolite of 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol 2001;14:1654-9. (Pubitemid 34016629)
66. Endogenous Hormones and Breast Cancer Collaborative Group: Body Mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
67. McTiernan A, Tworoger SS, Ulrich CM, Yasui Y, Irwin ML, Rajan KB, et al. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res 2004;64:2923-8. (Pubitemid 38500634)
68. Claus EB, Schildkraut JM, THompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-24. (Pubitemid 26162426)
69. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the consortium of investigators of modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 2007;9:104.
70. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37. (Pubitemid 41058322)
71. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.
72. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010;362:986-93.
73. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007;67:1893-7. (Pubitemid 46424203)
74. Kelley MK, Engqvist-Goldstein A, Montali JA, Wheatley JB, Schmidt DE Jr, Kauvar LM. Variability of glutathione S-transferase isoenzyme patterns in matched normal and cancer human breast tissue. Biochem J 1994;304:843-8.
75. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Aurup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239-48. (Pubitemid 34027754)
76. Hu X, Xia H, Srivastava SK, Herzog C, Awasthi YC, Ji X, et al. Activity of four allelic forms of glutathione S-transferase hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Commun 1997;238:397-402. (Pubitemid 27464396)
77. Hu X, Xia H, Srivastava SK, Pal A, Wasthi YC, Zimniak P, et al. Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[ c]phenanthrene and benzo[g]chrysene. Cancer Res 1998;58:5340-3. (Pubitemid 28551113)
78. Turing AM. The chemical basis of morphogenesis. Philos Trans R Soc Lond B Biol Sci 1952;237:37-72.
79. Key J, Hodgson S, Omar RZ, Jensen TK, Thompson SG, Boobis AR, et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control 2006;17:759-70.
80. Smith-Warner SA, Spiegelman D, Yaun SS, van der Brandt PA, Folsom AR, Goldbohn A, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998;279:535-40. (Pubitemid 28113433)
81. Gordon G, Southren AL, Vittek J, Lieber CS. The effect of alcohol ingestion on hepatic aromatase activity and plasma steroid hormones in the rat. Metabolism 1979;28:20-4. (Pubitemid 9118075)
82. Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, et al. The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women. Cancer Causes Control 1994;5:53-60. (Pubitemid 24066593)
83. Onland-Moret NC, Peeters PHM, van der Schouw YT, Grobbee DE, van Gils CH. Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study. J Clin Endocrinol Metab 2005;90:1414-9.
84. McDivit AM, Greendale GA, Stanczyk FZ, Huang MH. Effects of alcohol and cigarette smoking on change in serum estrone levels in postmenopausal women randomly assigned to fixed doses of conjugated equine estrogens with or without a progestin. Menopause 2008;15:382-5. (Pubitemid 351355004)
85. Horn-Ross P, Canchola A, West D, Stewart S, Bernstein L, Deapen D, et al. Patterns of alcohol consumption and breast cancer risk in the California Teachers Study cohort. Cancer Epidemiol Biomarkers Prev 2004;13:405-11. (Pubitemid 38737466)
86. Crooke PS, Parl FP. A mathematical model for DNA damage and repair. J Nucl Acids 2010;352:603-7.